Correlation Between Medigen Vaccine and Intech Biopharm

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Medigen Vaccine and Intech Biopharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Vaccine and Intech Biopharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Medigen Vaccine Biologics and Intech Biopharm, you can compare the effects of market volatilities on Medigen Vaccine and Intech Biopharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Vaccine with a short position of Intech Biopharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Vaccine and Intech Biopharm.

Diversification Opportunities for Medigen Vaccine and Intech Biopharm

-0.43
  Correlation Coefficient

Very good diversification

The 3 months correlation between Medigen and Intech is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Vaccine Biologics and Intech Biopharm in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Intech Biopharm and Medigen Vaccine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Vaccine Biologics are associated (or correlated) with Intech Biopharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Intech Biopharm has no effect on the direction of Medigen Vaccine i.e., Medigen Vaccine and Intech Biopharm go up and down completely randomly.

Pair Corralation between Medigen Vaccine and Intech Biopharm

Assuming the 90 days trading horizon Medigen Vaccine Biologics is expected to under-perform the Intech Biopharm. In addition to that, Medigen Vaccine is 1.14 times more volatile than Intech Biopharm. It trades about -0.04 of its total potential returns per unit of risk. Intech Biopharm is currently generating about 0.01 per unit of volatility. If you would invest  2,405  in Intech Biopharm on October 25, 2024 and sell it today you would earn a total of  15.00  from holding Intech Biopharm or generate 0.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Medigen Vaccine Biologics  vs.  Intech Biopharm

 Performance 
       Timeline  
Medigen Vaccine Biologics 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Medigen Vaccine Biologics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Medigen Vaccine showed solid returns over the last few months and may actually be approaching a breakup point.
Intech Biopharm 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Intech Biopharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Medigen Vaccine and Intech Biopharm Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Medigen Vaccine and Intech Biopharm

The main advantage of trading using opposite Medigen Vaccine and Intech Biopharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Vaccine position performs unexpectedly, Intech Biopharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intech Biopharm will offset losses from the drop in Intech Biopharm's long position.
The idea behind Medigen Vaccine Biologics and Intech Biopharm pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges